Non - Small Cell Lung Cancer
Conditions
Interventions
Experimental group:Sintilimab 200mg, Paclitaxel 135mg/m2, Cisplatin 75mg/m2 or Carboplatin AUC5 by intravenous infusion, combined with 6mg of Pegylated Recombinant Human
Control group:Sintilimab 200mg, Paclitaxel 135mg/m2, Cisplatin 75mg/m2 or Carboplatin AUC5 by intravenous infusion, once every 3 weeks
Sponsors
The Eighth People‘s Hospital of Jinan
Eligibility
Sex/Gender
All
Age
40 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. This study is mainly for Chinese small cell lung cancer with histologically or cytologically confirmed stage IV; 2. Age 6 months after the end of the last treatment.
Exclusion criteria
Exclusion criteria: 1. Those with an expected survival time of 30 Gy of lung radiotherapy in the past 6 months; 6. Those who are intolerant to PEG-rhG-CSF or camrelizumab or chemotherapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lymphocyte Subset Detection;TCR repertoire diversity and clonality; | — |
Secondary
| Measure | Time frame |
|---|---|
| TCRs are diverse Correlation of sex with changes in lymphocyte subsets; | — |
Countries
China
Contacts
Public ContactZhang Weike
The Eighth People‘s Hospital of Jinan
Outcome results
None listed